Filana Therapeutics, Inc. (FLNA) Stock Forecast
FLNA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 2 analysts
- Price target
- $6.50 average of analyst targets
- Upside to target
- +828.6% from the latest close
- Next earnings
- November 11, 2026
- 52-week range
- $0.68 – $4.41
FLNA analyst ratings
2 analystsNumber of analysts at each rating.
FLNA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
FLNA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.24 | −$0.25 | −$0.24 | −$0.22 | −11.4% | 2 |
| Current fiscal year (2026) | −$0.90 | −$0.92 | −$0.87 | −$1.88 | +52.4% | 2 |
| Next fiscal year (2027) | −$1.19 | −$1.19 | −$1.19 | −$0.90 | −33.0% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
FLNA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 2 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 2 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 1 |
FLNA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
FLNA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.25 | −$0.25 | −$0.24 | −$0.24 | −$0.24 | −2.0% | 1 up · 1 down |
| Current fiscal year (2026) | −$0.95 | −$0.95 | −$0.90 | −$0.90 | −$0.90 | −5.8% | 2 up · 0 down |
| Next fiscal year (2027) | $0.00 | −$1.19 | −$1.19 | −$1.19 | −$1.19 | — | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
FLNA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; FLNA beat in 7 of 9.
What analysts expect from FLNA
2 analysts cover Filana Therapeutics; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $6.50, 828.6% above the latest close of $0.70. Analysts expect earnings of −$0.90 per share for 2026, +52.4% from a year earlier. For 2027 the average estimate is −$1.19 per share. Filana Therapeutics beat the EPS estimate in 7 of the last 9 quarters.
Related: FLNA income statement, FLNA key metrics, FLNA chart. See the FLNA stock overview for the latest quote and news.
FLNA forecast FAQ
What is Filana Therapeutics's price target?
The average analyst price target for Filana Therapeutics is $6.50, 828.6% above the latest close of $0.70.
Is Filana Therapeutics a buy, hold or sell?
Of 2 analysts covering Filana Therapeutics, 1 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Filana Therapeutics's EPS forecast?
Analysts forecast −$0.90 per share for 2026 (range −$0.92 to −$0.87); for 2027 the estimate is −$1.19.
When does Filana Therapeutics report earnings?
Filana Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
Does Filana Therapeutics usually beat earnings estimates?
Filana Therapeutics reported EPS at or above the analyst estimate in 7 of the last 9 quarters.